Modality
Gene Therapy
MOA
CD3xCD20
Target
TYK2
Pathway
Notch
RSVRBSLE
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Aug 2026
Phase 2Current
NCT08549358
2,178 pts·SLE
2021-10→2026-08·Terminated
2,178 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-034mo awayPh2 Data· SLE
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2
Termina…
Catalysts
Ph2 Data
2026-08-03 · 4mo away
SLE
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08549358 | Phase 2 | SLE | Terminated | 2178 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| COR-9566 | Corcept | Approved | TYK2 | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | GPRC5D |